HRP20040996B1 - High drug load tablet - Google Patents

High drug load tablet

Info

Publication number
HRP20040996B1
HRP20040996B1 HR20040996A HRP20040996A HRP20040996B1 HR P20040996 B1 HRP20040996 B1 HR P20040996B1 HR 20040996 A HR20040996 A HR 20040996A HR P20040996 A HRP20040996 A HR P20040996A HR P20040996 B1 HRP20040996 B1 HR P20040996B1
Authority
HR
Croatia
Prior art keywords
drug load
high drug
tablet
load tablet
weight
Prior art date
Application number
HR20040996A
Other languages
English (en)
Croatian (hr)
Inventor
Luftensteiner Christian-Peter
Bainchi Jean-Claude
Ogorka J�rg
Kalb Oskar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040996(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20040996A2 publication Critical patent/HRP20040996A2/hr
Publication of HRP20040996B1 publication Critical patent/HRP20040996B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20040996A 2002-04-23 2004-10-22 High drug load tablet HRP20040996B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0209265A GB0209265D0 (en) 2002-04-23 2002-04-23 Organic compounds
PCT/EP2003/004151 WO2003090720A1 (en) 2002-04-23 2003-04-22 High drug load tablet

Publications (2)

Publication Number Publication Date
HRP20040996A2 HRP20040996A2 (en) 2005-06-30
HRP20040996B1 true HRP20040996B1 (en) 2010-11-30

Family

ID=9935351

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040996A HRP20040996B1 (en) 2002-04-23 2004-10-22 High drug load tablet

Country Status (32)

Country Link
US (6) US20050267125A1 (ru)
EP (1) EP1501485B1 (ru)
JP (4) JP2005529126A (ru)
KR (1) KR100728846B1 (ru)
CN (2) CN101653424A (ru)
AR (3) AR039335A1 (ru)
AT (1) ATE374016T1 (ru)
AU (1) AU2003229705C1 (ru)
BR (1) BR0309528A (ru)
CA (1) CA2483199C (ru)
CY (1) CY1106996T1 (ru)
DE (1) DE60316552T2 (ru)
DK (1) DK1501485T3 (ru)
ES (1) ES2290457T3 (ru)
GB (1) GB0209265D0 (ru)
GE (1) GEP20094627B (ru)
HK (1) HK1073253A1 (ru)
HR (1) HRP20040996B1 (ru)
IL (1) IL164678A (ru)
MX (1) MXPA04010496A (ru)
MY (1) MY136406A (ru)
NO (1) NO341027B1 (ru)
NZ (1) NZ536046A (ru)
PE (1) PE20031045A1 (ru)
PL (1) PL199779B1 (ru)
PT (1) PT1501485E (ru)
RU (2) RU2363450C2 (ru)
SI (1) SI1501485T1 (ru)
TN (1) TNSN04213A1 (ru)
TW (1) TWI350184B (ru)
WO (1) WO2003090720A1 (ru)
ZA (1) ZA200408441B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
PL1720853T3 (pl) 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
DK2422783T3 (en) 2005-05-26 2015-05-11 Sumitomo Dainippon Pharma Co Ltd pharmaceutical composition
ES2334933T3 (es) * 2005-08-15 2010-03-17 Siegfried Generics International Ag Comprimido recubierto o granulado que contiene una piridilpirimidina.
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
DE602007012122D1 (de) 2006-09-22 2011-03-03 Novartis Ag Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
JP2010540465A (ja) * 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド 安定なイマチニブ組成物
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
NZ590076A (en) 2008-06-27 2012-11-30 Univ Indiana Res & Tech Corp Treating plexiform neurofibroma and related tumors
US8697702B2 (en) 2008-12-01 2014-04-15 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
PL234542B1 (pl) * 2010-06-21 2020-03-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób otrzymywania kompozycji farmaceutycznej zawierającej imatinib lub jego farmaceutycznie dopuszczalną sól
US20130085145A1 (en) * 2010-06-21 2013-04-04 Suven Life Sciences Limited Imatinib mesilate pharmaceutical tablet
WO2012019633A1 (en) * 2010-08-11 2012-02-16 Synthon B.V. Pharmaceutical granulate comprising imatinib mesylate
TR201010618A2 (tr) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CN102552268A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种含有α晶型甲磺酸伊马替尼的药物制剂
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
CN102349874B (zh) * 2011-08-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼组合物及其制备方法
CN102349875A (zh) * 2011-10-11 2012-02-15 浙江华海药业股份有限公司 甲磺酸伊马替尼片的制备方法
KR20140096035A (ko) 2011-10-28 2014-08-04 노파르티스 아게 위장 기질 종양을 치료하는 방법
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EA026665B1 (ru) 2011-11-24 2017-05-31 Имунекс Фарма Илак Санайи Ве Тикарет А.С. Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
GB201204810D0 (en) 2012-03-20 2012-05-02 Pharos Pharmaceutical Oriented Services Ltd Pharmaceutical compositions
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
GB201304699D0 (en) 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
KR101520792B1 (ko) * 2013-04-10 2015-05-15 보령제약 주식회사 고부하 이매티닙 정제
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
CN104749226A (zh) * 2013-12-25 2015-07-01 辰欣药业股份有限公司 一种用电位滴定法测定甲磺酸伊马替尼含量的方法
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
CA3145658A1 (en) 2019-07-15 2021-01-21 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2001047507A2 (en) * 1999-12-27 2001-07-05 Novartis Ag Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH176497A (de) 1934-09-14 1935-04-15 Schmid Ernst Alarmvorrichtung.
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3751277A (en) * 1971-03-24 1973-08-07 Dow Chemical Co Tablet coating process and composition
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4639458A (en) 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
EP0277092B1 (de) * 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutisches System für schwerlösliche Wirkstoffe
JPS63267731A (ja) * 1987-04-23 1988-11-04 Asahi Chem Ind Co Ltd 錠剤組成物
JPH03501967A (ja) 1987-07-22 1991-05-09 ヨハン・ヴィッゴ・ファーベル エイズの処置に有用なフシジン酸
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
DE4031881C2 (de) 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5635208A (en) 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ES2179079T3 (es) 1993-10-12 2003-01-16 Mitsubishi Pharma Corp Comprimidos que contienen granulos entericos.
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5916593A (en) * 1994-09-22 1999-06-29 Akzo Nobel, N.V. Process of making dosage units by wet granulation
ES2079327B1 (es) 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5805889A (en) * 1995-10-20 1998-09-08 Sun Microsystems, Inc. System and method for integrating editing and versioning in data repositories
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
ES2173420T3 (es) 1996-02-29 2002-10-16 Fujisawa Pharmaceutical Co Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
JP3212531B2 (ja) * 1997-03-21 2001-09-25 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース崩壊剤及びその製造方法
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
IL136142A0 (en) 1997-11-17 2001-05-20 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations and processes for their manufacture
DE19758100B4 (de) * 1997-12-18 2006-05-04 Lichtwer Pharma Ag Verfahren zum Herstellen von Pflanzenextrakt enthaltenden pharmazeutischen Formulierungen
AU741992B2 (en) 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
UA72207C2 (ru) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
AU772726B2 (en) * 1998-08-12 2004-05-06 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
AU745282B2 (en) 1998-11-10 2002-03-21 Bayer Intellectual Property Gmbh Pharmaceutical moxifloxacin preparation
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
IT1311907B1 (it) 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
EA004872B1 (ru) 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
HU227045B1 (en) 1999-12-09 2010-05-28 Reckitt Benckiser Healthcare Compressed tablet composition comprising a nsaid
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
EP1263409A1 (en) 2000-03-03 2002-12-11 Ranbaxy Laboratories, Limited Orally administered controlled delivery system for once daily administration of ciprofloxacin
CN1208058C (zh) 2000-03-22 2005-06-29 法玛西雅厄普约翰美国公司 噁唑烷酮片剂的配方
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
CA2405793A1 (en) 2000-04-12 2001-10-18 Novartis Ag Combination of organic compounds
WO2001097805A2 (en) 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
JP4698000B2 (ja) 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
ATE492293T1 (de) 2001-02-27 2011-01-15 Senju Pharma Co Arzneimittelfreisetzungssystem aus einem biologisch abbaubaren polymer
AU2003216621A1 (en) * 2002-04-10 2003-10-20 The Government Of The United States The Department Of Veterans Affairs Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2001047507A2 (en) * 1999-12-27 2001-07-05 Novartis Ag Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Also Published As

Publication number Publication date
CA2483199C (en) 2010-08-17
WO2003090720A1 (en) 2003-11-06
MY136406A (en) 2008-09-30
KR100728846B1 (ko) 2007-06-14
PT1501485E (pt) 2007-12-18
PL199779B1 (pl) 2008-10-31
TNSN04213A1 (en) 2007-03-12
CY1106996T1 (el) 2012-09-26
JP2015143250A (ja) 2015-08-06
GB0209265D0 (en) 2002-06-05
JP2013079271A (ja) 2013-05-02
JP2010031019A (ja) 2010-02-12
ZA200408441B (en) 2005-08-31
AU2003229705A1 (en) 2003-11-10
JP2005529126A (ja) 2005-09-29
CN1646103A (zh) 2005-07-27
AU2003229705B2 (en) 2007-01-25
GEP20094627B (en) 2009-03-10
AU2003229705C1 (en) 2017-09-07
MXPA04010496A (es) 2004-12-13
US20120177737A1 (en) 2012-07-12
IL164678A (en) 2014-02-27
EP1501485B1 (en) 2007-09-26
PE20031045A1 (es) 2004-02-10
US20050267125A1 (en) 2005-12-01
ATE374016T1 (de) 2007-10-15
AR072755A2 (es) 2010-09-22
JP5752107B2 (ja) 2015-07-22
EP1501485A1 (en) 2005-02-02
HRP20040996A2 (en) 2005-06-30
BR0309528A (pt) 2005-02-15
DK1501485T3 (da) 2007-12-27
HK1073253A1 (en) 2005-09-30
JP5798269B2 (ja) 2015-10-21
TWI350184B (en) 2011-10-11
US20100203133A1 (en) 2010-08-12
DE60316552T2 (de) 2008-07-03
SI1501485T1 (sl) 2008-08-31
NO341027B1 (no) 2017-08-07
US20160101105A1 (en) 2016-04-14
US20150209291A1 (en) 2015-07-30
AR084101A2 (es) 2013-04-24
KR20040101550A (ko) 2004-12-02
NZ536046A (en) 2007-08-31
AR039335A1 (es) 2005-02-16
IL164678A0 (en) 2005-12-18
US20140135340A1 (en) 2014-05-15
US9011911B2 (en) 2015-04-21
CN101653424A (zh) 2010-02-24
TW200404009A (en) 2004-03-16
RU2363450C2 (ru) 2009-08-10
ES2290457T3 (es) 2008-02-16
CA2483199A1 (en) 2003-11-06
NO20045072L (no) 2005-01-20
PL371495A1 (en) 2005-06-27
DE60316552D1 (de) 2007-11-08
RU2004134323A (ru) 2005-08-10
RU2405540C1 (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
HRP20040996B1 (en) High drug load tablet
MY148773A (en) Galenic formulations of organic compounds
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
PA8586501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
DK0991407T3 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
RS50360B (sr) Farmaceutske formulacije derivata platine
TW200603841A (en) Dispersible tablets comprising a benzoic acid derivative
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
MY138734A (en) Casr antagonist
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20064834L (no) Forlenget frigivelse av sammensetninger som omfatter torasmid og en matriksdannende polymer.
ATE551999T1 (de) P-glycoprotein-hemmer mit octiloniumbromid als wirkstoff
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
WO2008065144A3 (en) Galenic formulations of organic compounds
ECSP055804A (es) Composición farmacéutica
RS52818B (sr) Farmaceutska formulacija sa kontrolisanim otpuštanjem koja sadrži natrijum alginat i natrijum kalcijum alginat
HRP20040165B1 (en) Citalopram for the treatment of elevated blood pressure
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
SE0402640D0 (sv) Pharmaceutical use
TH40574A (th) อนุพันธ์ของไฮดรอกซีคิวมาราโนนที่ถูกแทนที่ที่ 0 ในฐานะที่เป็นสารต่อต้านเนื้องอกและต่อต้านการแพร่กระจายเซลเนื้อร้าย

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190401

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200330

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210420

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220421

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230422